. Models of all previously reported major melanoma subtypes (BRAF, NRAS, NF1, KIT, and WT/ WT/WT) were identified. Multiple minor melanoma subtypes were also recapitulated, including melanomas with multiple activating mutations in the MAPK-signaling pathway and chromatin-remodeling gene mutations. These well-characterized melanoma PDXs and cell lines can be used not only as reagents for a large array of biological studies but also as pre-clinical models to facilitate drug development.
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Garman et al. have characterized melanoma PDXs and cell lines described in Krepler et al. (see the related paper in this issue of Cell Reports), identifying major and minor subtypes, some of which were previously not well defined, targeted and immunotherapy resistance, and tumor heterogeneity, creating a set of reagents for future drug discovery and biological studies.
INTRODUCTION
Although cancer incidence overall declined in the United States from 2002 to 2011, the incidence rates of melanoma continue to rise (Ryerson et al., 2016) . If diagnosed early, surgical resection is curative in most melanoma patients. However, roughly 20% of patients will develop metastatic disease. Melanoma accounts for approximately 50,000 deaths per year worldwide, over 75% of skin cancer-related mortality (Corrie et al., 2014) . With the cost of massively parallel sequencing technologies decreasing at a rapid rate, precision medicine is routinely practiced, in which the genetic profile of a patient's melanoma is obtained and used to guide diagnosis and treatment. This practice is particularly valuable for melanoma due to the malignancy's severity and the availability of effective targeted therapies for common mutations (Robert et al., 2015) .
Melanoma is characterized by constitutive activation of the mitogen-activated protein kinase (MAPK)-and/or phosphoinositide 3-kinase (PI3K)-signaling pathways and disruption of the cell cycle. Approximately 45% of melanomas harbor an activating mutation affecting codon 600 of the serine/threonine-protein kinase BRAF (BRAF V600E), against which targeted inhibitors (BRAFis) were developed (Davies et al., 2002; Chapman et al., 2011; Krepler et al., 2016) . BRAFis provide clinical benefit to a large percentage of advanced melanoma patients whose tumors harbor a BRAF V600E mutation. However, median progression-free survival is approximately 6 months (Chapman et al., 2011; Hauschild et al., 2012) . Combining BRAFi with MEK inhibitor (MEKi) therapy increases responses rates and approximately doubles median progression-free survival (Robert et al., 2015) . Nevertheless, drug resistance is still a major hurdle in the long-term management of melanoma with targeted therapies (Wagle et al., 2014) . Simultaneously, immune checkpoint inhibitors have been increasingly used for melanoma treatment. These agents (anti-CTLA-4, anti-PD-1, and anti-CTLA-4/anti-PD1) have demonstrated increasing rates of responses in clinical trials, many of which are durable (i.e., >2 years) (Larkin et al., 2015) . Targeted and immunotherapy combinations are currently being explored.
In recent years, several large-scale massively parallel sequencing studies have provided valuable insights into the genetics of melanoma. Initial whole-exome sequencing studies demonstrated that NF1, ARID2, PPP6C, RAC1, SNX31, TACC1, and STK19 are significantly mutated genes in melanoma Krauthammer et al., 2012) . The Cancer Genome Atlas Skin Cutaneous Melanoma (SKCM-TCGA) exome sequencing dataset identified several additional significantly mutated melanoma genes, namely, MAP2K1, IDH1, RB1, and DDX3X (Cancer Genome Atlas Network, 2015) . The same groups classified melanomas into genetic subtypes as follows: BRAF mutant, RAS mutant, NF1 mutant, and the triple wild-type (WT/WT/WT). Rare, low-frequency, driver mutations were identified in the WT/WT/WT subtype in KIT, CTNNB1, GNA11, and GNAQ. Additionally, an apparent increase in copy number variation (CNV) frequency in WT/WT/WT, particularly copy number amplifications, was detected in driver genes. Further, wholeexome sequencing studies revealed that NF1 mutant melanomas frequently carry additional mutations in other MAPKsignaling pathway genes (Krauthammer et al., 2015; Arafeh et al., 2015) .
As sequencing of patient tumors continues to reveal the widespread genetic variability of melanomas, there is a critical need for genetically annotated melanoma translational models that accurately recapitulate the biology and molecular characteristics of the patient's original tumor for use in pre-clinical studies to develop personalized treatment strategies. We sequenced genes previously implicated in melanomagenesis to evaluate mutations and copy number changes in 115 human melanoma cell lines, 248 patient-derived xenografts (PDXs), 31 cell lines derived from PDXs (PDX CLs), and 68 patient tumors (462 samples total). Of the patients with melanoma, 263 were treatment naive and 54 were previously exposed to immunotherapy with anti-CTLA-4 or anti-PD-1, 34 to targeted therapy with BRAFi and/or MEKi, and 20 to a combination of targeted and immunotherapy.
RESULTS
Demographic and Clinicopathological Characteristics of Sequenced Cell Lines, PDXs, Patient Tumors, and PDX CLs Sequencing was performed on cell lines, PDXs, and patient tumors. Of 115 Wistar Melanoma cell lines generated at the Wistar Institute, partial characterization has been reported on a subset (Hoek et al., 2006; Lin et al., 2008) Table S1 ; further details can be found in the companion paper . Twenty-two samples (6% of unique cohort) were non-cutaneous melanomas, with mucosal (10, 3%), acral cutaneous (7, 2%), and uveal (5, 1%) primaries included.
Variability among Cell Lines, PDXs, PDX CLs, and Patient Tumors Tumors were sequenced on a custom capture panel of 108 genes (MEL V1) known to be important in melanomagenesis (Table S2 ). The full genes (exons and introns) were sequenced for tumor suppressors to facilitate copy number calling, with a few exceptions. Exons only were sequenced for oncogenes. We developed an in-house annotation pipeline to classify variants as deleterious, likely deleterious, and of unknown significance (see the Experimental Procedures and Figure S1 ). Variants and copy number alterations (CNAs) were identified in all 108 targeted genes. A subset (101) was sequenced on a 119-gene panel (MEL V2) (Table S3) ; 106 genes were shared with MEL V2. Of 101 samples (36 unique patients), 45 were sequenced on both panels, enriched for non-BRAF V600E/K/D and non-NRAS Q61 mutant samples. The deleterious/likely deleterious variant concordance rates of MEL V1 and MEL V2 were 94% (217 of 231 MEL V1 variants found on MEL V2) and 97% (217 of 223 MEL V2 variants found on MEL V1) ( Figure S2 ). Testing results for mutations in the major driver melanoma genes (BRAF, RAS, NF1, and KIT) did not differ.
Following variant calling, all 115 cell lines harbored at least one deleterious mutation, compared to 236 of 248 PDXs (95%), 30 of 31 PDX CL (97%) samples, and 59 of 68 patient tumors (87%). Likely deleterious mutations were found in 69 of 115 cell lines (60%), 168 of 248 PDXs (67%), 18 of 31 PDX CLs (58%), and 36 of 68 patient tumors (53%). Variants of unknown significance (VUSs) were found in 103 of 114 cell lines (90%), 222 of 248 PDXs (93%), 27 of 31 PDX CLs (87%), and 55 of 68 patient tumors (81%). Table S5 lists all called variants in our cohort. Among all four sample types, the total number of calls (deleterious/likely deleterious/VUS) did not differ significantly ( Figure 1B) . However, the alternate allele fractions (AAFs) of variants detected across all sample types were statistically significant different (p = 2.2 3 10 À16 ). Patient tumors had the lowest AAF, presumably due to admixture with non-tumor cells, and PDX CLs had the highest AAF ( Figure 1C) . We compared the prevalence of common mutations across the four sample types. In the samples from the 371 unique individuals, 203 (55%) had mutations in BRAF, 72 (19%) in RAS (NRAS and KRAS), and 22 (6%) in NF1 ( Figure 1D ). As discussed in detail below, some samples had mutations in more than one of these genes, and for this purpose they were included in the most prevalent mutation group (e.g., those with BRAF and RAS mutations in the BRAF mutant group and those with RAS and NF1 mutations in the RAS group). Seventy-four samples (20%) did not have mutations in the above genes (WT/WT/WT); 14 WT/WT/ WT were non-cutaneous melanomas (acral [1, 1%] , mucosal [9, 12%], or uveal [4, 6%] ). For nine WT/WT/WT tumor biopsies, the sample provided may have been normal tissue, as we only identified one to three VUSs at 50% allele frequency in each; four did not grow in mice and five have not been tested for growth. Cell lines had a higher prevalence of both deleterious BRAF and RAS mutations than PDXs and patient tumors (p = 0.05; Figure 1D ). CDKN2A mutations and homozygous deletions occurred at a higher frequency (74, 68%) in cell lines, compared to 104 (52%) PDXs and 14 (24%) tumors (p = 3.3 3 10 À7 ). TP53 mutations and homozygous deletions also occurred at a higher frequency in cell lines (34%), as compared to PDXs (23%) and tumors (21%), but not significantly. Figure S3C ). The genes most frequently homozygously deleted were the following: CDKN2A (130, 65.3%), CDKN2B (102, 51.3%), PTEN (47, 23.6%), and TP53 (12, 6%) ( Figure S3D ). A complete list of CNAs can be found in Table S6 .
MAPK-Signaling Pathway Mutations
The mutational landscape of our samples revealed two distinct patterns of mutations within the MAPK-signaling pathway: (1) single-hotspot BRAF or NRAS mutations; and (2) multiple nonhotspot variants across different genes encoding proteins within the MAPK-signaling pathway, including NF1 mutations. Across our naive and immunotherapy cohort (317 patients, 85% of unique cohort), 206 melanomas representing unique individuals (65% of naive and immunotherapy cohort) followed pattern 1; 148 had solitary driver mutations in BRAF (72%) and 58 (28%) in NRAS. Pattern 2 melanomas representing 52 unique individuals (14% of unique; 16% of naive and immunotherapy cohort) had more than one deleterious or likely deleterious mutation in either an MAPK-signaling gene or in a gene encoding an effector protein of the MAPK pathway, as shown in Table 1 . Three pattern 2 samples were acral (2) and mucosal (1). Eighteen samples harbored a deleterious or likely deleterious non-V600 BRAF mutation (p.H57Y, p.G464E, p.S465Y, p.G466E, p.G469E, p.L496V, p.N581S, p.N581Y, p.D594G, p.V624F, p. K601E, and p.600_601del) ( Figure S4 ). We also noted an additional six non-V600 BRAF mutations, which we designated as VUSs but that may have functional significance (p.G7S, p.F294L, p.S365L, p.S365L, p.A497V, and p.T740A). We also identified five BRAF non-V600 variants (p.G9A, p.L505H, p.P318S, p.P328S, and p.A366P) in samples also carrying V600E mutations, which are less likely to be functional. All non-V600 BRAF mutations had concurrent deleterious/likely deleterious mutations or high-level amplifications in other MAPK-signaling genes. Co-occurring RAS deleterious mutations were most frequent, found in 60% of non-hotspot BRAF mutant samples as compared to 2%, 6.3%, and 21.5% of those with BRAF V600E, V600K, and other BRAF hotspot mutations, respectively (p < 0.0001). Most melanomas had a single second deleterious mutation in a MAPK-signaling gene; a few had three. We identified concurrent mutations or amplifications in other MAPKsignaling pathway genes in all BRAF non-V600 codon mutations, except for one, which had incomplete sequencing.
Twenty-three RAS mutants had co-occurring mutations in the MAPK-signaling pathway (Table 1; Figure S4 ), and, therefore, they fell into pattern 2, compared to 58 pattern 1 RAS mutant samples (53, 91% Q61; 5, 9% non-Q61). Eleven Q61 (17% of all Q61) and 13 non-Q61 (75% of all non-Q61) mutated melanoma samples harbored additional mutations in the MAPKsignaling pathway (p = 2.2 3 10 À16 for enrichment of non-Q61 mutations). Of the 30 NF1-mutated melanomas, 26 (87%) harbored concurrent deleterious/likely deleterious MAPKsignaling pathway mutations (Table 1) . Two of the remaining four NF1-mutated melanomas had VUSs in MAP3K5 (WM4242 also had a deleterious mutation in ROS1 [c.780-1G > A]). Of the four possible mutations observed in RASA2 (one truncating and three likely deleterious missense), only two were observed in NF1 mutant samples. Four of nine (44%) KIT mutant samples also carried concurrent MAPK pathway mutations.
Four wild-type (WT/WT/WT) samples in this cohort harbored likely deleterious and deleterious mutations in MAP2K1/2 and MAP3K5, including one with a truncating deleterious mutation in MAP3K5 (p.E477X) ( Figure S5 ).
Genetic/Genomic Landscape of Sequenced Naive Melanoma Cell Lines, PDXs, PDX CLs, and Patient Tumors Deleterious mutations, homozygous losses, and high-level copy number amplifications in the 225 naive-to-treatment samples are shown in Figure 2 ; only one sample from each patient is included. Likely deleterious mutations and other genomic aberrations also are included in Figure S6 . As deleterious TERT promoter mutations (Table S4) were detected in 67% of samples, and ubiquitously in all subtypes, they are not included in Figures 2 and S6A.
Within BRAF-V600E mutant treatment-naive samples, we observed previously well-described subtypes. Of 105, 44 (42%) BRAF V600E-mutated samples from unique patients harbored truncating and/or deleterious missense mutations in cell cycle genes (CDKN2A, CDK4, and/or TP53). The remaining 61 (58%) BRAF V600E-mutated samples had more frequent homozygous loss of CDKN2A/B (46% versus 25%; p = 0.03), but not PTEN (25% versus 11%). Homozygous deletions in PTEN occurred almost exclusively in BRAF V600E samples (91%) (p < 0.0001). Within the subset of BRAF V600E-mutated samples lacking additional CDKN2A, CDK4, and/or TP53 mutations, 10 samples (9.5% of unique patients) lacked the C > T nucleotide substitution pattern characteristic of UV sun damage (Brash, 2015) , possibly due to low mutation burden. NF1 mutant samples had the highest overall mutational burden of all subtypes (p = 1 3 10 À6 ), the majority of which were C > T transitions. Of 11 NF1 mutant samples from unique patients, seven samples (64%) harbored a deleterious mutation in TP53, more frequently than in other subtypes (p = 0.003). Ten of 29 WT/WT/WT (34.5%) harbored previously reported rare mutations in GNAQ, GNA11, and CTNNB1, in a mutually exclusive fashion, six of which were uveal PDX and cell lines. A further two WT/WT/WT samples (7%) were acral and mucosal melanomas. Multiple samples displayed high-level copy number amplifications. Of 27, 19 (70%) high amplifications in MITF occurred in BRAF V600E-mutated samples. Of the 12 co-occurrences of high amplification in FGF3/4 and/or CCND1, nine (75%) also harbored high amplification in MITF. FGF3, FGF4, and CCND1 are co-localized at 11q13.3, explaining co-occurrence, whereas MITF is on chromosome 3, suggesting a synergistic effect. Of 31, 25 (80.6%) concurrent amplifications in BRAF, MET, and/or EZH2 occurred in BRAF hotspot mutant samples (p = 0.009). Three very high-level BRAF amplification events (6-to 16-fold) were identified, two of which were in BRAF V600K mutants. Finally, 14 of 24 (58%) high-amplification events in NOTCH2 co-occurred with high amplification in NRAS; both are on 1p. Of note, WT/WT/WT patients harbored significantly lower numbers of CNAs compared to hotspot BRAF and RAS subtypes (p < 1 3 10 À4 ), but not to NF1-mutated samples.
We performed formal correlation analyses to examine cooccurrence of copy number changes that were found in more than 10% of samples (Figures S6B and S6C) . When all samples were considered, significant correlations were identified between co-localized genes, such as deletion of CDKN2A/ CDKN2B (9p21.3) and amplifications of PREX2/SNX31/MYC (8q) and BRAF/RAC1/EGFR/EZH2/GRM3/DYNC1I1/CDK6/MET (chr 7). Significant correlations between non-co-localized genes also were observed, with the most significant being between MITF amplification and CDKN2A deletion (p = 0.0005), MITF and EGFR amplifications (p = 0.0005), and STK19 and AKT3 amplifications (p = 2 3 10 À5 ) ( Figure S6B ). The first two correlations are due to co-enrichment in BRAF-mutated samples. Within the BRAF mutant subset, the only correlation that emerged was between MYC and STK19 amplifications (p = 0.0001) (Figure S6C) . Little is known about STK19 in melanoma; these data suggest further functional evaluation is warranted.
Genetic Landscape of Melanoma Cell Lines, PDXs, PDX CLs, and Patient Tumors Exposed to Targeted Therapies Forty-nine (54 samples) unique patients had samples taken either post-progression (37) or on treatment (12) with targeted therapy; 21 (43%) were treated with a combination of BRAFi and MEKi, 27 (55%) BRAFi alone, and one MEKi alone (Figure 3A) . Post-progression PDXs were expanded in vivo on a continuous BRAFi or BRAFi/MEKi to maintain the resistance phenotype (Krepler et al., 2016) . Twenty (41%) patients received a combination of targeted and immunotherapy.
Potential resistance mechanisms were identified for 29 of 36 (81%) patients that progressed on treatment ( Figure 3B ) and classified into four categories: BRAF high-level amplifications (10, 28%), NRAS mutant (6, 17%), MAP2K1 mutant (p.C121S, p.K57E/N, p.P124S, and p.Q56P) (7, 19%) , and non-MAPK pathway alterations (MITF and MET high amplification and PTEN homozygous loss) (5, 14%). Although no deleterious mutations in MAP2K2 were identified, a VUS (p.K61E) was found in the non-MAPK pathway-altered group, which may be associated with resistance. MAP2K2 p.K61E has been reported in a patient with cardio-facio-cutaneous syndrome, one of the Rasopathies, supporting a functional role (Dentici et al., 2009 ). Additional genetic and genomic changes were observed that also may contribute to therapeutic resistance ( Figure 3B ). Homozygous loss of PTEN and high-level amplification of MET were seen in 20% and 50% of patients with high-level amplification of BRAF, respectively. High-level amplification of BRAF was observed in 67% of samples also having secondary NRAS Q61/G12 mutations, along with additional CNAs in non-MAPK pathway genes. The mechanisms of resistance found in the samples did not differ between patients treated with BRAFi alone and with BRAFi/MEKi.
Genetic Landscape of Melanoma Cell Lines, PDXs, PDX CLs, and Patient Tumors from Patients Treated with Immunotherapy Overall, 71 unique patients (two acral) were previously exposed to immunotherapy with anti-CTLA4 (33, 46%), anti-PD-1 (19, 27%), or anti-CTLA4/anti-PD1 (19, 27%). Twenty patients (28%) received both immunotherapy and targeted therapy. Of the 71 patients, eight (11%) patients were responders (one acral), 33 (47%) had progressive disease, seven (10%) had stable disease, and one patient (1%) had a mixed response (Figure 4) . Disease outcome was unknown for 22 (31%) patients (one acral). The genetic and genomic landscape was similar to the naive sample set, with an enrichment for non-BRAFmutated tumors. However, mutational burden (nonsynonymous variants/mb) in patients that received immunotherapy was significantly higher than the naive cohort (p = 0.03).
Evaluation of Multiple Samples from the Same Patient
Multiple samples from 40 patients were sequenced, including cell lines, PDXs, PDX CLs, and biopsies ( Figure S7 ; Table S7 ). Full mutational concordance was observed across 65 samples from 28 (70%) patients; 35 samples from 12 patients were discordant. In six instances, discordance could be attributed to within-patient tumor heterogeneity, three instances to within-tumor heterogeneity, one instance to the development of acquired resistance mutations, two to acquired resistance mutations in cell lines adapting to targeted therapy, and in two instances no potential etiology could be identified. Discordant deleterious mutations in KRAS (p.A146T and p.K117N), PTEN, and TACC1 were found in two biopsies taken on the same day but from different locations in a patient progressing on pembrolizumab/dabrafenib (WM4420). One patient had a total of five biopsies at three different time points; discordant mutations were observed in three genes, varying over time (before and after treatment with ipilimumab) and location (WM4295). We also observed discordant mutations in five genes in biopsies taken from left and right axillary lymph node metastases (WM4413). Further, an early-intransit metastasis was found to have a deleterious TP53 mutation, with two subsequent biopsies from different locations, while the patient was on BRAFi therapy for 12 months, both TP53 WT (WM4011). Interestingly, the thick primary melanoma differed remarkably from a residual lung metastasis after anti-CTLA4 therapy (WM4210). We also observed two instances in which tumor grafts from the same PDX expanded in different mice did not have the same mutational changes.
These data suggest that intra-tumoral heterogeneity can lead to the outgrowth of several sub-clones during the propagation of PDX, and they may explain some of the heterogeneity seen in PDX efficacy studies (Krepler et al., 2016) . Therapeutic pressures also can lead to new mutations conferring selective growth advantages. In the BRAF V600E mutant model WM4351, two PDXs derived from therapy-naive biopsies were both NRAS WT, whereas a biopsy taken after progression on BRAFi/MEKi had an NRAS Q61K mutation. In two cases, PDXs derived from targeted therapy-progressed patients did not demonstrate any acquired mutations, but they were resistant to the same therapy the patient had received when dosed in vivo. When we established cell line cultures, they initially did not grow, but they became resistant after several passages. Each cell line had a resistance mutation, one in NRAS (Q61K allele frequency 0.44) and the other in MAP2K1 (C121S allele frequency 0.43) ( Table S7 ).
Chromatin-Remodeling Gene Mutations in Melanoma
Cell Lines, PDXs, PDX CLs, and Patient Tumors Mutations in the genes that encode the SWI/SNF chromatinremodeling enzymes ARID1A (BAF250A/SMARCF1), ARID1B (BAF250B), ARID2 (BAF200), and SMARCA4 (BRG1) have been implicated in melanoma, as have those that encode other chromatin organization/histone modification proteins (EZH1, EZH2, SETD2, and TRRAP) Cancer Genome Atlas Network, 2015) . Overall, 65 of 371 (17.5%) samples from unique patients harbored a likely deleterious/deleterious mutation in at least one of the genes associated with chromatin remodeling or chromatin organization/histone modification (Figure 5) . The most frequently mutated were ARID2 (23), followed by ARID1A (13), ARID1B (7), and SMARCA4 (4). Deleterious mutations in ARID2, ARID1A, and SMARC4 were mutually exclusive (p = 2.2 3 10 À16 ), apart from a co-occurrence of ARID2 and SMARCA4 in one sample. However, deleterious mutations in ARID1B were found concurrently with mutations in ARID2 (1) and ARID1A (2). Restricting to naive samples to reduce bias, BRAF V600E mutations were the least likely to be associated with chromatin-remodeling gene mutations (7 of 105, 7%). Chromatin-remodeling gene mutations were observed comparatively frequently with BRAF V600K (3 of 15, 20%), RAS (12 of 50, 24%), and NF1 (1 of 11, 9%) mutations (p = 0.013). One deleterious truncating mutation was detected in EZH1; deleterious/likely deleterious missense mutations were found in 12 EZH1/2-mutated samples from unique patients. Rare mutually exclusive mutations were found in SETD2 (4), TRRAP (4), IDH1 (1), and BAP1 (1).
Comparison of Genotypes in Clinical Samples and PDXs
Clinical tumor sequencing data from 79 melanoma patients treated at Penn Medicine or MDACC were compared to our data (Table 2) . At the Center for Personalized Diagnostics at Penn Medicine, the TruSeq Amplicon Cancer Panel (Illumina) was used for clinical sequencing (Hiemenz et al., 2016) . At MDACC, CMS50 (Life Technologies) was used for clinical sequencing . For each patient, mutational profiles of PDX or tumor biopsy were compared to the clinical mutational profile. It is important to note that, in virtually all cases, a different sample was used for clinical sequencing than to establish the PDX or sent as a research tumor biopsy.
Additionally, we could only compare samples for which positive results were found on either clinical or study sequencing in regions covered by both. All deleterious mutations were determined to be such by both the site and study. However, for six likely deleterious mutations and VUSs, the pathogenicity calls varied. Overall, there were 101 potentially overlapping mutations, of which 91 (91%) were found by both the site and study. We identified eight of 63 (12.6%) samples with discordant results. Of those, four (WM3407, WM4428, WM4462, and WM4464) research biopsies were likely normal tissue rather than melanoma, as they had one to three VUSs at allelic frequencies of 50%. For two samples (WM4433 and WM4323), although clinical sequencing was done on a pre-treatment sample, we sequenced a post-treatment sample and identified presumably de novo resistance mutations. In one sample (WM4279), we identified a KIT p.L576P mutation not found in the clinical samples. Of the 16 UPENN samples with sequencing of a clinical sample and PDX, we only found one (6%) with discrepant results; interestingly, we each found different truncating mutations in PTEN. We observed that mutations tended to have higher allele frequencies in the PDX, as compared to clinical sequencing, which could be due to either admixture in the original tumor or loss of the wild-type allele during establishment of the PDX, which we have observed for ovarian cancer PDX (George et al., 2017). 
DISCUSSION
In this era of precision medicine, pre-clinical drug development of targeted oncology therapeutics relies heavily on models of cancer that have been shown to be representative of the genetic profile of the patient's tumor. Herein, we demonstrate that targeted massively parallel sequencing of 108/119 genes previously implicated in melanomagenesis, followed by our custom analysis pipelines for mutational and CNV calling, is a reliable method for characterizing the genetic and genomic landscape of melanoma cell lines, tumors, PDXs, and PDX CLs. To account for the lack of matched normal samples, control samples were sequenced in each lane for normalization for copy number calling and to identify common variants, which were subtracted out. We also removed sequences that more closely aligned to the mouse than human genome to decrease cross-contamination and increase accuracy of mutational and copy number calling. We used an in-house-developed pipeline to classify mutations or variants as deleterious, likely deleterious, and VUS, incorporating information from the literature and Catalogue of Somatic Mutations in Cancer (COSMIC), mutational type, location, and effect, after filtering for a maximum population frequency greater than or equal to 0.1% to account for the lack of a matched normal. We found the total number of mutation and variant calls did not differ significantly among cell lines, PDXs, PDX CLs, and patient tumors, although, not surprisingly, there was a trend toward higher mutational rates in PDXs and cell lines. We observed significantly higher rates of BRAF and RAS mutations and CDKN2A mutations/loss in cell lines than PDXs and tumor biopsies, consistent with the growth advantage conferred by those mutations. However, we did find cell lines representing all mutational groups. We also found an extremely high concordance rate between clinical sequencing results and our targeted sequencing, with only two samples of 80 (2.5%) demonstrating truly discrepant results. Taken together, the mutational profiles observed in the melanoma cell lines, PDXs, and PDX CLs sequenced in this study are an accurate genetic and genomic representation of the patient's original tumor. We also identified all major previously reported melanoma subtypes, as well as the full spectrum of mutations and copy number aberrations, at roughly the same frequencies identified in large-scale original patient tumor/normal sequencing studies (Berger et al., 2012; Hodis et al., 2012; Krauthammer et al., 2015; Cancer Genome Atlas Network, 2015) . Thus, we have a unique genetically and genomically annotated biobank of PDXs, PDX CLs, and cell lines, representative of the full spectrum of melanoma, which can be used both for functional studies and pre-clinical drug development studies in melanoma.
Our large sample set also enabled us to describe rare subtypes in greater detail. We found two mutually exclusive patterns of mutations in the MAPK-signaling pathway: (1) single-hotspot mutations at BRAF V600 or NRAS Q61; and (2) multiple non-hotspot variants across different genes encoding proteins within the MAPK-signaling pathway, of which NF1 mutations are a subset. All deleterious/likely deleterious non-600 mutations in BRAF, 87% of the NF1, 75% of the non-Q61 RAS, and 44% of KIT mutant samples harbored either a secondary mutation or highlevel amplification in at least one gene encoding a MAPKsignaling protein or an effector protein of the MAPK pathway. These data are consistent with functional studies that have demonstrated that kinase-dead BRAF (D594 mutants) needs oncogenic RAS to drive tumor progression (Heidorn et al., 2010) . Our results also suggest that BRAF mutations (e.g., at G464 and G469) leading to constitutive dimerization (Yao et al., 2015) also need at least one additional MAPK-signaling mutation to drive tumor progression, either a single NRAS G12/13 or multiple other mutations. These data suggest that, to accurately characterize therapeutic response pre-clinically for non-V600 BRAF or non-Q61 NRAS mutations, a second MAPK-signaling mutation will be needed to be included in the model. Further, we can make predictions about the functionality of uncharacterized BRAF non-V600 mutations, in that if the alteration is found without a secondary MAPK-signaling pathway gene mutation or in the presence of a BRAF V600 gene mutation, it is very unlikely to have any functional significance. Similar to BRAF non-V600 mutations, RAS G12/13 mutations usually are observed with co-occurring mutations, most commonly in BRAF and NF1, suggesting they are not sufficient to drive tumorigenesis in melanoma, in contrast to other tumor types (Hobbs et al., 2016) .
We identified additional MAPK pathway or co-activating gene mutations in 87% of NF1 mutant tumors. We did not observe any difference between those with one or two truncating NF1 mutations or with accompanying loss of the wild-type allele. Prior literature has suggested an enrichment for co-occurring mutations in Rasopathy genes, particularly PTPN11 and RASA2 (Arafeh et al., 2015; Cirenajwis et al., 2017; Krauthammer et al., 2015) . However, we observed co-occurrence of deleterious mutations across numerous genes without specific enrichment, including those that have not been previously implicated as co-mutated with NF1, although known to be mutated in melanoma, MAP3K5 and MAP3K9. Functional studies of BRAF wt /RAS wt melanoma cell lines lacking NF1 expression, or expressing NF1 at extremely low levels, have shown that not all have RAS activation and that only some were sensitive to MEKi (Krauthammer et al., 2015) . This result may be explained by the co-occurrence of other MAPK-signaling gene mutations. Pre-clinical modeling of response to therapies for NF1-mutated melanoma also will need to account for co-occurring mutations. The NF1 mutant cohort harboring co-mutations in MAPK3K5/9 is of particular interest, as they are upstream activators of the Jun N-terminal kinase (JNK) and p38 MAPK pathways (Rana et al., 2013) . The current study provides the reagents to further functionally characterize this interesting rare subtype of melanoma. Although previous sequencing studies have identified ARID1A/B, ARID2, IDH1, SMARCA4A, TRRAP, and EZH2 as chromatin-remodeling genes frequently mutated in melanoma (Berger et al., 2012; Hodis et al., 2012; Zhang et al., 2016) , their mutual exclusivity has not been well described. Given this finding, it is likely that the previously described ARID1B dependence in ARID1A-mutated ovarian cancer cells (Helming et al., 2014) is recapitulated in melanoma, as well as the EZH2 dependency in tumors with mutations in ARID1A or SMARCA4 that do not harbor co-mutations in RAS or BRAF (Kim et al., 2015) . However, a few ARID1A-and SMARCA4-mutated samples in our dataset do have co-mutations in BRAF or RAS, which has been postulated to abolish EZH2 dependency (Kim et al., 2015) , so further investigation is needed. The biological relevance of the likely deleterious missense mutations we identified in ARID1A/B and ARID2, which occur alone and concurrently with other ARID1A/B and EZH2 mutations, also needs to be evaluated functionally. Pre-clinical studies using these PDX models may reveal other specific vulnerabilities in melanomas, with a mutation in SWI/SNF components ARID1A, ARID1B, ARID2, or SMARCA4A, that will aid in the development of novel therapeutics.
We profiled 37 PDXs, PDX CLs, and tumor biopsies from patients that progressed on targeted therapy (either BRAFi or BRAFi/MEKi). Our evaluation for resistance mechanisms was limited by a lack of matched pre-treatment or normal samples and RNA to evaluate for splice variants or potential fusions. However, we identified mutations in NRAS, MAP2K1, and BRAF amplification at rates similar to other series (Johnson et al., 2015) . Amplification of BRAF was enriched in this set (40%), as compared to the naive group (15%, p = 2 3 10 À4 ). For the two PDXs with high-level BRAF amplifications, it likely is the primary mechanism of resistance. For other samples with BRAF amplification, it is a potential mechanism of resistance, but it cannot not be definitively proven as we lacked matched pre-treatment samples. For 51% of samples, we did not identify a clear mechanism of resistance; in half of those, we found amplifications and drivers outside the MAPK-signaling pathway that may be associated with resistance. We also profiled PDXs, PDX CLs, and tumor biopsies from 71 patients that had received checkpoint blockade therapy. The genetic and genomic landscape of these samples was similar to naive samples, albeit with increased mutational burden and enrichment for non-BRAF mutations. These post-treatment PDXs are ideal for further studies to identify potential resistance mechanisms and pre-clinical studies of potential therapeutics for tumors resistant to either targeted or checkpoint therapy. Our study has several limitations, when compared to prior tumor-based analyses. Although the samples are derived from human tumors, they are established in culture or as PDX models in T cell-deficient (nude) mice, so they are not subject to an intact immune system, which may lead to differential selective pressures for mutations or copy number aberrations. Additionally, intra-tumor heterogeneity observed in PDX expansion (Tentler et al., 2012) can result in potentially inharmonious PDX/PDX CL and tumor mutational profiles. We observed a high consistency between clinical testing and our profiling, likely because the former mainly included major driver genes. However, when we sequenced multiple samples from the same individual, we found several instances of both within-patient and within-tumor heterogeneity. Further, several of the tumor biopsies (but neither PDXs nor cell lines) that we sequenced that fall into the WT/WT/WT group may be normal tissue, as histopathology was not done on these research samples. Platform and analytical differences also may lead to differences among mutational and copy number rates among studies. As we did not have a matched normal sequence for subtraction, we used population-based data, non-matched normal and stringent calling metrics to identify deleterious and likely deleterious mutations, but these are imperfect controls. We also chose to only report out high-level amplifications and homozygous deletions, to be conservative. Thus, for some genes, our data appear different than prior studies. For example, mutations in GRIN2A and TRRAP are reported in 22% and 12%, respectively, of melanomas in a meta-analysis of somatic mutations across studies (Zhang et al., 2016) ; but, since we classified most variants in these genes as VUSs, our reported rates of deleterious/likely deleterious mutations are much lower at 6% and 5.6%. Additionally, we are limited by the genes and regions included in our panel at the time of design, and so we have not interrogated recently identified recurrently mutated promoter regions, genes associated with resistance to checkpoint blockage, and the Rasopathy genes in all samples. Performing unbiased whole-exome or whole-genome sequencing on 462 samples was not possible due to cost restrictions.
This unparalleled biobank of melanoma cell lines, PDXs, and PDX CLs in this study provides a set of reagents for not only future melanoma drug discovery and development efforts but also extensive biological studies. We have characterized 146 cell lines (31 derived from PDXs), 248 PDXs, and 68 tumor biopsies, which include both those naive to treatment and resistant to targeted therapy and checkpoint blockade. We have been able to identify all major and minor subtypes of melanoma, thus providing reagents that, in some cases, were previously unavailable for functional and biological studies. Although further evaluation will need to be done in some instances to characterize the reagents (e.g., targeted therapy progression samples for which no mechanism of resistance was identified), the current genetic and genomic copy number data provide a strong basis for future studies. These reagents enable thoughtful pre-clinical trials to be designed to determine the in vivo efficacy of novel single-agent and combination therapies in genetically defined melanoma subsets, as demonstrated in the companion paper .
EXPERIMENTAL PROCEDURES
Sample Acquisition Acquisition of patient samples for the purposes of establishing PDXs and cell lines was approved by the corresponding institutions' institutional review boards, and informed consent was obtained from each participant for use of his or her sample in genetic studies. Tumors were provided from the following institutions: Perelman School of Medicine at the University of Pennsylvania, MD Anderson Cancer Center, Helen F. Graham Cancer Center, Massachusetts General Hospital, the John Wayne Cancer Institute, the Center for Melanoma and Cancer Immunotherapy at Hadassah Hebrew University Medical Center's Sharett Institute of Oncology, and the University of Duisburg-Essen.
A full description of PDX development is given in our companion paper (Krepler et al., 2016) . As part of this study, 114 human melanoma cell lines, 246 PDXs, 60 PDX CLs, and 68 patient tumors were sequenced (total number of samples: 462) (Table S1 ). In addition to melanoma cell lines, PDXs, and PDX CLs, 36 unmatched anonymous germline blood samples were sequenced simultaneously, which were used for the normalization for copy number calling.
Processing of Sequencing Data
Short-read sequences were aligned to the GRCh37 human reference genome using the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2009 ). Duplicate reads were flagged, as well as reads that mapped equally to more than one location. Human reads were further disambiguated from mouse by aligning to the mm10 reference genome using the Python script (https://github.com/AstraZeneca-NGS/disambiguate), which takes the human_aligned.bam and the mouse_aligned.bam as input. Reads that aligned more confidently to the mouse genome, as well as ambiguous reads between the two species, were discarded. To achieve acceptable data quality assurance, the Broad Institute's Genome Analysis Toolkit (GATK) ''Best Practices'' guidelines were followed. Single-nucleotide variant (SNV) and small insertion and deletion (indel) variant calling was performed by GATK UnifiedGenotyper (DePristo et al., 2011; McKenna et al., 2010) , VarDict (Lai et al., 2016) , and Freebayes (Garrison and Marth, 2012) . Variants with a read depth less than 20 and alternative allele read depth less than five, as well as all synonymous variants, and/or variants present in the germline samples, were excluded. However, variants that were called by more than one variant caller and had a sequencing depth of less than 20 were not excluded. Variants were annotated with a customized version of ANNOVAR (Wang et al., 2010) . Variants were removed if the minor allele frequency was greater than or equal to 0.1% in the population databases 1000 Genomes (Abecasis et al., 2012) and/or Exome Aggregation Consortium (ExAC) (Lek et al., 2016) or found in normal germline samples sequenced on our capture. The remaining annotated variants were classified as outlined in Figure S1 . Variant classification was confirmed with cBioPortal for Cancer Genomics, wherever possible (Cerami et al., 2012) , and using ClinVar for the Rasopathy genes (https://www.ncbi.nlm.nih.gov/clinvar/). Integrative Genomics Viewer was used for visual confirmation of the majority of calls (Thorvaldsdó ttir et al., 2013) .
CNV Prediction
CNV from sequencing data were profiled using copy number detection by exome sequencing (CODEX) (Jiang et al., 2015) . CODEX normalizes depth of coverage using a Poisson latent factor model that removes biases due to GC content, exon capture and amplification efficiency, and latent systemic artifacts. Six Poisson latent factors were included in the normalization model for this dataset, which corresponds to sample-and targetwise biases and artifacts that cannot be directly measured or quantified. Segmentation was restricted to exons for all genes. Only homozygous loss (copy number < 0.7) and high-amplification (copy number > 3.3) calls are reported. Visual confirmation of CNV calls was done in Nexus 7.5 (BioDiscovery) software.
Biostatistical Analysis
RStudio version 1.0.136 was used to analyze the data. One-way ANOVA was used to compare the means of variant calls in cell line, PDX, and PDX CL. Paired t test (along with 95% confidence interval for the difference in means) was used to compare allelic fractions of all variants, the number of all filtered variants among all sample types, the mutational burden between patients that received immunotherapy and naive ones, and mutational burden comparison of naive NF1 mutants, with other naive subtypes. Chi-square test, Fisher's exact test, or an unpaired t test was used to make other statistical comparisons, as appropriate. For cluster analysis based on correlations, a gene with CNV < 1 or > 1 was selected for data analysis if it was shown from more than 10% of study samples. Spearman correlation coefficients were calculated between each pair of selected genes, and hierarchical clustering by Euclidian distance and complete linkage using the heatmap.2 function available from the R Foundation for Statistical Computing (http://www.R-project. org) was further performed to group the genes based on their correlations. For all analyses, p < 0.05 was considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the targeted sequencing data reported in this paper is Sequence Read Archive (SRA): SUB2649393. 
